Reactivation of Retinopathy of Prematurity After Ranibizumab Treatment

Wong, Ryan; Hubschman, Sasha; Tsui, Irena

doi:10.1097/iae.0000000000000578

Cited by 112 publications

(105 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hu et al [24] presented 9 patients with reactivation of ROP after IVB injection. Wong et al [25] reported reactivations after IVR injection but not after IVB injection; they thought this might be due to the shorter half-life of ranibizumab. In our study, there was no significant difference between groups regarding the reactivation of ROP.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Kimyon

Mete²

2018

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Methods: Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone 1 were evaluated retrospectively. Spherical equivalent (SE) and axial length (AXL) measurements were performed at 1 year of adjusted age. Results: Sixty-eight eyes of 37 patients were included in the study. All patients had initial disease regression but 6 patients (4 in the IVB, 2 in the IVR group) showed reactivation (p = 0.679). The number of eyes with incomplete vascularization were 15 and 12 in the IVB and IVR groups, respectively (p = 0.725). Mean AXL was 20.50 ± 0.99 mm in the IVB group and 19.30 ± 0.48 mm in the IVR group (p < 0.001). Mean SE was –1.49 ± 2.38 dpt in the IVB group and 0.98 ± 2.18 dpt in the IVR group (p < 0.001). Conclusion: Bevacizumab and ranibizumab showed similar effectiveness in the treatment of type 1 ROP affecting zone 1. The AXL was longer and SE was more myopic in eyes treated with IVB. This difference might be caused by the longer intravitreal half-life of bevacizumab than ranibizumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Kimyon

Mete²

2018

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Wong et al [14] reported ROP reactivation in 5/6 eyes treated with IVR, whereas none of four eyes treated with IVB experienced reactivation. The reports by Wong and Erol seem to contradict the conclusion presented by Chen suggesting that IVB and IVR are equally effective, despite the fact that all three studies utilized the same dosage of anti-VEGF agents.…”

Section: Focus On Ranibizumab Versus Bevacizumabmentioning

confidence: 97%

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity

Patel

Ranjan

Wasserman

2016

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Wong et al [25] found that reactivation after ranibizumab occurred between the 41st and 42nd weeks. In the present study, recurrence was observed in the postmenstrual 43rd week on average in the bevacizumab group and in the postmenstrual 42.2nd week on average in the ranibizumab group.…”

Section: Discussionmentioning

confidence: 99%

The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab

Sukgen

Çömez²,

Koçluk³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the effects on the process of retinal vascularization of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of severe retinopathy of prematurity. Methods: The present study is a bi-centered retrospective study. While 44 eyes of 22 patients in group 1 were applied 0.625 mg bevacizumab, 46 eyes of 23 patients in group 2 were applied 0.25 mg ranibizumab. Retinal vascularization was evaluated clinically. Results: The mean time for completion of vascularization was found to be postmenstrual 55.93 ± 4.13 weeks in group 1 and 56.30 ± 4.30 weeks in group 2. There were signiﬁcant differences in the recurrence prevalence between the two groups. The prevalence of recurrence was found to be significantly higher in the ranibizumab group than in the bevacizumab group (p = 0.023). Conclusions: The study showed that after IVR or IVB treatment, vascularization could be completed with delay; there were no differences in this delay time between the ranibizumab and bevacizumab groups. Besides, avascular areas may remain in the peripheral retina, and additional treatment may be necessary after IVB or IVR treatment. When the treatment was applied as monotherapy, more recurrence was observed in the ranibizumab group.

show abstract

Reactivation of Retinopathy of Prematurity After Ranibizumab Treatment

Abstract: The role of anti-VEGF treatment for ROP is still being evaluated. Although the shorter half-life of ranibizumab makes it an attractive option, reactivation of ROP is possible. Physicians and families should be aware of this to follow infants closely for an extended period of time.

Cited by 112 publications

References 19 publications

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity

The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab

Contact Info

Product

Resources

About